[allAfrica] Almost six years ago, we embarked on a journey to address one of the deadliest diseases on the African continent - malaria. In 2019, Burkina Faso, where nearly 5,000 children die from malaria every year, became the centre of the R21 malaria vaccine Phase II trial. What began as a scientific challenge for my colleagues and I, turned into a historic public health achievement that we can all take pride in.